In particular, therapeutic inhibition of cathepsins was the driving force in the field since the discovery that cathepsin K has a crucial role in bone resorption and thus in osteoporosis [37,104,185,186], and that cathepsin S is the key enzyme in the MHC II-mediated immune response [29,31]. Here, CTSK is linked to osteoporosis.